Janssen signs exclusive deal for multivalent vaccine development with GlycoVaxyn
This article was originally published in Scrip
Executive Summary
Johnson and Johnson subsidiary, Janssen Pharmaceuticals has finalized an exclusive license agreement with vaccine developer, GlycoVaxyn, entering a three-year research collaboration to develop a multi-valent bacterial vaccine employing the firm’s bio-conjugation technology.